

30 November 2023

ASX ANNOUNCEMENT

2023 Annual General Meeting - Results of Meeting

Set out below are the results of the Annual General Meeting of ImpediMed Limited (ASX.IPD) (**ImpediMed** or **Company**) held earlier today. All resolutions put to the meeting were decided by a poll.

As announced to the ASX on 20 November 2023, Dr Michael Seiden resigned as a director of the Company, and therefore the resolution in Item 5 was withdrawn.

Item	Resolution	Result			
2	Remuneration Report	Passed as an advisory resolution			
3	Re-election of McGregor Grant as a director of the Company	Passed as an ordinary resolution			
4	Re-election of Christine Emmanuel-Donnelly as a director of the Company	Passed as an ordinary resolution			
5	Election of Dr Michael Seiden as a director of the Company	Withdrawn			

In accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and ASX Listing Rule 3.13.2 the results of the Annual General Meeting are provided in the attached document.

Approved for release by the Company Secretary, Leanne Ralph.

Contact Details

Investor Relations Contact:

Hannah Howlett WE Communications T: +61 450 648 064

E: hhowlett@we-worldwide.com
E: investorrelations@impedimed.com



About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen atrisk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancerrelated lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.



IMPEDIMED LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING Thursday, 30 November, 2023

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)			Direct vote (as at proxy close):		Total votes cast in the poll (where applicable)				
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	For	Against	Abstain **	Result
2	REMUNERATION REPORT	N	521,565,732 65.14%	130,665,341 16.32%	8,266,504 1.03%	14,386,402	100,326,223 12.53%	39,808,217 4.97%	687,691,267 80.01%	171,839,333 19.99%	14,386,402	Carried
3	RE-ELECTION OF MR MCGREGOR GRANT	NA	649,175,970 77.83%	17,009,324 2.04%	8,266,504 0.99%	432,181	154,116,104 18.48%	5,480,521 0.66%	873,815,387 97.36%	23,720,615 2.64%	432,181	Carried
4	RE-ELECTION OF MS CHRISTINE EMMANUEL-DONNELLY	NA	649,175,970 77.83%	17,009,324 2.04%	8,266,504 0.99%	432,181	154,116,104 18.48%	5,480,521 0.66%	873,815,387 97.36%	23,720,615 2.64%	432,181	Carried
5	ELECTION OF DR MICHAEL SEIDEN	NA	593,219,110 77.63%	1,904,133 0.25%	9,428,189 1.23%	70,332,547	60,445,188 7.91%	99,151,437 12.98%	Not put to meeting	Not put to Meeting	Not put to Meeting	

^{** -} Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item

Res	Resolution proposed but not put to the meeting					
No.	Short Description	Reason(s) for not putting to the meeting				
5	ELECTION OF DR MICHAEL SEIDEN	Resolution Withdrawn				